Thanks Naomi!
Danielle
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/BYAPR08MB54321202315B5FD82715546FB9B39%40BYAPR08MB5432.namprd08.prod.outlook.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/a7a514c8-a51a-4de5-aade-7749b63d9ff1n%40googlegroups.com.
Hi all,
I am not aware of any major issue with the data in that file, so there shouldn’t need to be any rerunning of analyses. You can always double check with the Diagnostic Summary file, which is the file that ADNIMERGE draws from to fill in the diagnosis information – you just have to be aware that across phases of ADNI, the variables for capturing diagnosis changed (in ADNI-1, it was DXCURREN, in ADNI-GO/2, it was DXCHANGE and in ADNI-3 it was DIAGNOSIS – the coding for all of those variables is available in the study Data Dictionary (available in the same section of the Study Data page as the ADNIMERGE file and separate from the ADNIMERGE data dictionary).
Elina, if you want to email me directly (djha...@ucdavis.edu) some specific RIDs where the diagnosis information disappeared in ADNIMERGE, I can look into it and then respond to the group…
Danielle
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/CABHhyW5nipVmjem9Xwsj%3DXHLAa14nFyYfNzRuXD982oANTh2zA%40mail.gmail.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/BYAPR08MB4872B04BBAF66592239F3E96C0B29%40BYAPR08MB4872.namprd08.prod.outlook.com.
Confidentiality Notice:
This email and any attachments may be confidential and protected by legal privilege. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the e-mail or any attachment is prohibited. If you have received this email in error, please notify us immediately by replying to the sender and then delete this copy and the reply from your system. Thank you for your cooperation.
C4X Discovery Ltd Registered in England and Wales Registered Number: 06324250 Registered Office: Manchester One, 53 Portland Street, Manchester M1 3LD, UK.
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/CAGfQw%2BvSGfZhQznUr_N8YdRR38Mf0uhX_A2KfNkYkwmBDGGukA%40mail.gmail.com.
That is correct…
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/CABHhyW7Y2aR%2Bh-h4_r%3D1--BAx_srkOzZGEfmcxYYVO7Z7OfP2g%40mail.gmail.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/BYAPR08MB487285762A92C6E851D4DE30C0B29%40BYAPR08MB4872.namprd08.prod.outlook.com.
Yes, ADNIMERGE contains all participants across all phases of ADNI.
Danielle
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/CAGfQw%2BtFs1%3Db0%2BjLGyXQiN4nOKe%2BPkwvpdB%2BOarJ8TTzLNNM-Q%40mail.gmail.com.
Hi Elina,
I had Naomi look a bit more closely into the specific participants you had sent so we can clarify a bit about the DX and DX_bl variables in ADNIMERGE.
First, DX_bl (though misleading as a variable name) is actually the screening diagnosis for ADNI-1, GO, 2 (though not in ADNI-3). The screening diagnosis is the diagnosis made at the screening visit, which is based off a subset of information needed to determine eligibility for the study…the screening diagnosis also determined the visitation schedule for an individual. At the baseline visit, a more complete assessment of each participant is done and another diagnosis is made. The Clinical Core generally recommends using the baseline diagnosis as it is based on more information. For most individuals, the diagnosis at the screening visit and the baseline visit are the same, but there are a handful of participants for which it changes. These changes are not thought to be true “progressions” or “reversions” in diagnosis, but rather a better classification of the individual based on the full assessment.
The screening and baseline visits collect different sets of information, so ADNIMERGE, for simplicity, combines all variables collected at either visit into the VISCODE==”bl” row. DX_bl is the screening diagnosis, while DX at VISCODE==”bl” will have the baseline diagnosis. For ADNI-3, DX_bl just uses the diagnosis at the baseline visit.
Individuals who have DX_bl, but a missing DX (for VISCODE==”bl”) are individuals who went to the screening visit, but never went on for the baseline visit, so they did not get a baseline diagnosis…they most likely did not continue in the study, so we just have information for them at the screening visit.
If DX_bl is missing and the RID (or numbers following _S_ in PTID) is greater than 6000, this is an individual newly enrolled or screened as part of ADNI-3 (so they were not part of an earlier phase of ADNI). Since, DX_bl is missing and for ADNI-3, the DX_bl is drawing from the baseline visit, these are individuals who do not go on for the baseline visit. If you are interested in their screening diagnosis, you will find it in the Diagnostic Summary file for VISCODE==”sc”.
I hope this clarifies the issues around DX and DX_bl, especially at baseline…
Danielle
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/a7a514c8-a51a-4de5-aade-7749b63d9ff1n%40googlegroups.com.
In ADNI-GO/2/3, we had used sub-categories of EMCI (early MCI) and SMC (normal but with subjective memory concern) to expand the variability within the MCI and CN groups. In ADNI-3, the focus for recruitment was on CN, MCI, and mild dementia, but the definition for CN included “with or without subjective memory concern” and MCI included both EMCI and LMCI. So, the specific designations of SMC or EMCI or LMCI were not captured. You can refer to the summary of key eligibility criteria on page 3 in the ADNI-2 Clinical Protocol (available under Clinical Protocols: ADNI | Study Documents (usc.edu)) should you want to try to implement an algorithm to identify SMC/EMCI/LMCI in ADNI-3.
To view this discussion on the web visit https://groups.google.com/d/msgid/adni-data/f27949b6-ac30-4241-8569-4af97fecb7bcn%40googlegroups.com.